Xilio Therapeutics (XLO) Interest Coverage Ratio (2020 - 2026)
Xilio Therapeutics (XLO) posted Interest Coverage Ratio of 742.74 for Q1 2026, down 69.43% sequentially from 438.37 in Q4 2025, and down 216.38% YoY from 638.21 in Q1 2025.
Xilio Therapeutics (XLO) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Interest Coverage Ratio for 7 years, with the latest figure at 742.74 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 216.38% year-over-year to 742.74 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2223.32 (down 130.35% YoY) and the FY2025 annual result came in at 0.33, up 37.84% from the prior year.
- Interest Coverage Ratio declined to 742.74 in Q1 2026 per XLO's latest filing, from 438.37 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 18.47 in Q4 2022 and troughed at 742.74 in Q1 2026.
- A 5-year average of 194.96 and a median of 106.12 in 2022 frame the typical range for Interest Coverage Ratio.
- The widest YoY moves for Interest Coverage Ratio: up 90.55% in 2022, down 9030.53% in 2022.
- Over 5 years, Interest Coverage Ratio stood at 18.47 in 2022, then slumped by 334.23% to 80.22 in 2023, then surged by 39.75% to 48.33 in 2024, then plunged by 807.04% to 438.37 in 2025, then plunged by 69.43% to 742.74 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 742.74, 438.37, and 28.37 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.65 Bn | 131.79 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.08 Bn | 78.09 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 63.25 Bn | 58.11 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.26 Bn | 27.95 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.96 Bn | 10.57 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.19 Bn | 26.35 Bn | - | 1.42 |
| 10 | Xilio Therapeutics | 177.07 Mn | 41.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.06 |
| Mar 31, 2026 | -742.74 |
| Dec 31, 2025 | -438.37 |
| Sep 30, 2025 | -28.37 |
| Jun 30, 2025 | -368.36 |
| Mar 31, 2025 | -234.76 |
| Dec 31, 2024 | -48.33 |
| Sep 30, 2024 | -149.11 |
| Jun 30, 2024 | -84.02 |
| Mar 31, 2024 | -55.69 |
| Dec 31, 2023 | -80.22 |
| Sep 30, 2023 | -403.74 |
| Jun 30, 2023 | -261.25 |
| Mar 31, 2023 | -112.56 |
| Dec 31, 2022 | -18.47 |
| Sep 30, 2022 | -92.26 |
| Jun 30, 2022 | -89.93 |
| Mar 31, 2022 | -106.12 |
| Dec 31, 2021 | -195.56 |
| Sep 30, 2021 | -1.01 |